Off-label use of JAK inhibitors can prove beneficial in the treatment of several dermatologic conditions. Casey Butrus, PharmD: I wanted to bring back up the mechanism of action of the topical JAK ...

PARIS — In a study that employed change in inflammatory biomarkers as a primary endpoint, hair regrowth with ritlecitinib, a dual JAK3/TEC inhibitor, was observed across three types of cicatricial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. JAK inhibitors inhibit a broader cytokine profile than ...

Dr Rosmarin illustrates treatment management of vitiligo with the use of JAK inhibitors. David Rosmarin, MD: Our JAK inhibitors have shown the most promise. Ruxolitinib cream 1.5% twice a day has gone ...

The Phase II OCULE-01 study in uveal melanoma started in March 2025, the PULMO-01 study in non-small cell lung cancer (NSCLC) started in May 2025 and the HEMA-MED Phase I/II study in myelofibrosis ...

Onctura initiates phase I/II trial of roginolisib in patients with myelofibrosis who are no longer responding to JAK inhibition: Geneva, Switzerland Friday, December 5, 2025, 15: ...

Use of Janus kinase (JAK) inhibitors is associated with a nearly fourfold increase in risk of acne compared with placebo, according to an analysis of 25 JAK inhibitor studies. Acne has been reported ...

Please provide your email address to receive an email when new articles are posted on . Janus kinase inhibitors have delivered on some, but not all, of the promises that were expected of them upon ...

The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for cases where a patient may not be appropriate for a TNF blocker, drugmaker ...

Relief for the pain and stiffness of ankylosing spondylitis often starts with nonsteroidal anti-inflammatory drugs (NSAIDs) and then biologics, but it doesn't always end there. If these medicines ...

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs ...

Newer oral medications for rheumatoid arthritis (RA) do work quite well in the "real world," despite some doubts that they would, according to a new study. The study, of 622 adults with RA, found that ...